Back to Search Start Over

Germline BRAF Mutations in Noonan, LEOPARD, and Cardiofaciocutaneous Syndromes: Molecular Diversity and Associated Phenotypic Spectrum

Authors :
Efisio Puxeddu
Giorgia Esposito
Angelo Selicorni
Cesare Rossi
Anna Sarkozy
Sonia Moretti
Maria Lisa Dentici
Marco Tartaglia
Grazia M.S. Mancini
Bruno Dallapiccola
Francesca Pantaleoni
Margherita Silengo
Viviana Cordeddu
Maria Cristina Digilio
Laura Mazzanti
Anna Paola Scioletti
Franco Stanzial
Luigi Memo
Bruno Marino
Giovanni Battista Ferrero
Francesca Faravelli
Claudio Carta
Giuseppe Zampino
Francesca Romana Lepri
Bruce D. Gelb
Valentina Petrangeli
Liborio Stuppia
Clinical Genetics
A. Sarkozy
C. Carta
S. Moretti
G. Zampino
M.C. Digilio
F. Pantaleoni
A.P. Scioletti
G. Esposito
V. Cordeddu
F. Lepri
V. Petrangeli
M.L. Dentici
G.M. Mancini
A. Selicorni
C. Rossi
L. Mazzanti
B. Marino
G:B. Ferrero
M.C. Silengo
L. Memo
F. Stanzial
F. Faravelli
L. Stuppia
E. Puxeddu
B.D. Gelb
B. Dallapiccola
M. Tartaglia.
Source :
Human Mutation, 30(4), 695-702. Wiley-Liss Inc.
Publication Year :
2009
Publisher :
Wiley-Liss Inc., 2009.

Abstract

Noonan, LEOPARD, and cardiofaciocutaneous Syndromes (NS, LS, and CFCS) are developmental disorders with overlapping features including distinctive facial dysmorphia, reduced growth, cardiac defects, skeletal and ectodermal anomalies, and variable cognitive deficits. Dysregulated RAS-mitogen-activated protein kinase (MAPK) signal traffic has been established to represent the molecular pathogenic cause underlying these conditions. To investigate the phenotypic spectrum and molecular diversity of germline mutations affecting BRAF, which encodes a serine/threonine kinase functioning as a RAS effector frequently mutated in CFCS, subjects with a diagnosis of NS (N = 270), LS (N = 6), and CFCS (N = 33), and no mutation in PTPN11, SOS1, KRAS, RAF1, MEK1, or MEK2, were screened for the entire coding sequence of the gene. Besides the expected high prevalence of mutations observed among CFCS patients (5296), a de novo heterozygous missense change was identified in one subject with LS (17%) and five individuals with NS (1.9%). Mutations mapped to multiple protein domains and largely did not overlap with cancer-associated defects. NS-causing mutations had not been documented in CFCS, suggesting that the phenotypes arising from germline BRAF defects might be allele specific. Selected mutant BRAF proteins promoted variable gain of function of the kinase, but appeared less activating compared to the recurrent cancer-associated p.Val600Glu mutant. Our findings provide evidence for a wide phenotypic diversity associated with mutations affecting BRAF, and occurrence of a clinical continuum associated with these molecular lesions. Hum Mutat 30, 695-702, 2009. (C) 2009 Wiley-Liss, Inc.

Details

ISSN :
10981004 and 10597794
Volume :
30
Issue :
4
Database :
OpenAIRE
Journal :
Human Mutation
Accession number :
edsair.doi.dedup.....3395af1ad78aa7e0376b2bb505bc74b5